| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
87 |
| Employees |
100 |
| Revenues (TTM) (Millions $) |
37 |
| Net Income (TTM) (Millions $) |
-67 |
| Cash Flow (TTM) (Millions $) |
-107 |
| Capital Exp. (TTM) (Millions $) |
10 |
Business Description
Progenics Pharmaceuticals Inc. is an American biomedical company that is focused on the development of novel, targeted therapies for cancer and other diseases. The company was founded in 1986 in Tarrytown, New York, and is headquartered in New York City.
Progenics Pharmaceuticals has a pipeline of drug candidates that are based on its platform technology, which involves the use of antibodies and peptides to target specific disease-related molecules or cells. Some of the drug candidates in the pipeline are in various stages of clinical trials, from early-stage studies to Phase III trials.
One of the key products in Progenics Pharmaceuticals' portfolio is AZEDRA (iobenguane I 131), which is designed to treat rare and difficult-to-treat tumors such as pheochromocytoma and paraganglioma. The drug was approved by the U.S. Food and Drug Administration (FDA) in July 2018 and launched commercially in early 2019.
Another product in the company's pipeline is PyL, a prostate-specific membrane antigen (PSMA)-targeted PET imaging agent that is designed to improve the detection and localization of prostate cancer. The drug is currently in a Phase III clinical trial.
Progenics Pharmaceuticals has also developed a technology platform for radiotherapeutic agents, which involves the use of targeted radiation therapy to deliver high doses of radiation directly to cancer cells. One of the products based on this technology is 1095, an antibody-drug conjugate that is currently in Phase II clinical trials for the treatment of prostate cancer.
The company has collaborations with several pharmaceutical companies, academic institutions, and government agencies around the world, including Salix Pharmaceuticals, Curis, and the National Cancer Institute.
Progenics Pharmaceuticals has a team of experienced scientists, researchers, and executives who are dedicated to discovering and developing innovative therapies for cancer and other diseases. The company has been recognized for its contributions to the field of cancer research, and its research has been published in numerous peer-reviewed journals.
|
%